The Cost and Evolution of Quality at Cipla Ltd., 1935–2016
研究了印度制药公司西普拉如何逐步达到欧美监管机构的质量标准，分析了其从1935年创立起基于民族主义的自力更生文化，以及1960年代至2000年代初采用质量控制技术、在艾滋病疫情中树立全球声誉等关键因素。
This article examines the evolution of Indian pharmaceutical manufacturer Cipla toward producing drugs that met the quality standards of European and U.S. regulators. It employs new research in both Cipla's corporate archives and a wide range of oral histories. The article argues that, along with a long-standing corporate culture of self-reliance rooted in nationalism starting from the company's inception in 1935, major factors in Cipla's strategy from the 1960s through the early 2000s included the early adoption and continued use of quality-control technology, along with efforts to create global goodwill for affordable high-quality generic drugs during the HIV/AIDS epidemic of the early 2000s.